Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)

The summary for the Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed): The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The FOA will utilize the U54 (Specialized Center--Cooperative Agreements) activity code. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion.

Federal Grant Title:	Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-21-054
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.394, 93.396
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 2nd, 2021
Original Application Deadline:	November 2nd, 2021
Posted Date:	August 31st, 2021
Creation Date:	August 31st, 2021
Archive Date:	December 8th, 2021
Total Program Funding:
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 31st, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-054.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate C...; • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...; • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Cli...; • Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Cli...; • Specialized Alcohol Research Centers (P50 Clinical trial Optional); • Comprehensive Alcohol Research Centers (P60 Clinical trial Optional); • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)